Health & Fitness
Health and Fitness
Health and Fitness 
Mon, February 28, 2011
Sun, February 27, 2011
Sat, February 26, 2011
Fri, February 25, 2011
Goldman Scarlato & Karon, P.C. Announces Investigation of Clinical Data, Inc.
CONSHOHOCKEN, Pa.--([ BUSINESS WIRE ])--Goldman Scarlato & Karon, P.C. (aGSKa) isinvestigating potential legal claims against the Board of Directors of Clinical Data, Inc. (aClinical Dataa) (NASDAQ: CLDA) relating to the proposed buyout of Clinical Data by Forest Laboratories, Inc. The definitive acquisition agreement, announced on February 22, 2011, involves an all-cash, going-private transaction valued at approximately $1.2 billion, or $30.00 per share. The acquisition price reflects an 11.5 percent discount to Clinical Dataa™s February 18, 2011 closing price of $33.90.
The investigation relates to the fairness of the proposed transaction to Clinical Data shareholders, possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Clinical Data for approving this transaction, and whether Clinical Dataa™s Board of Directors acted inshareholdersa™ best interests.
If you currently own shares of Clinical Data/CLDA and would like additional information regarding this investigation, or if you have information regarding the allegations involved in this transaction, please contact Mark S. Goldman, Esq.at (888) 668-4130 or by email at [ goldman@gsk-law.com ].
About Goldman Scarlato & Karon, P.C.
GSK prosecutes securities fraud, consumer fraud, price-fixing, ERISA class actions, and shareholder-derivative actions throughout the United States. The Firma™s lawyers have recovered hundreds of millions of dollars on behalf of consumers, investors, and businesses.
To learn more about GSK, you may visit[ www.gsk-law.com ].